A research team consists of Kyoto Prefectural University of Medicine, Kansai Medical University Hospital, and National Institute of Advanced Industrial Science and Technology has developed a new drug screening method focusing on protein structure and clarified resistance the resistance mechanism of MEK inhibitors. They identified RPS5 (ribosomal protein S5) as a target protein of two natural plant components with cancer-inhibitory activity, and revealed that RPS5 is involved in the cell death resistance of the MEK inhibitor trametinib, one of the molecular target drugs. In addition, a new drug screening method has been developed that uses ABCI, a supercomputer, to search for drug candidate molecules by focusing on the structure of the protein.
The results were published in the scientific journal PNAS nexus on May 16, 2022 (local time).
Paper tile: A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5
URL: (Japanese Only)